What is the purpose of this trial?
This is an open label, multi-drug, biomarker-directed, multi-centre, multi-arm, randomised Phase 1b study in patients with muscle invasive bladder cancer (urothelial) who have progressed on prior treatment. This study is modular in design, allowing evaluation of the safety, tolerability, pharmacokinetics and anti-tumour activity of multiple agents as monotherapy and as combinations of different novel anti-cancer agents in patients with muscle invasive bladder cancer.
The study will consist of a number of study modules (substudies), each evaluating the safety and tolerability of a specific agent or combination.
Ages: 18 - 130 years
Astra Zeneca, L.P.
Start Date: 05/18/2017
End Date: 02/16/2018
Last Updated: 02/22/2018
Study HIC#: 1601017024